[Re-resection for recurrent intrahepatic cholangiocarcinoma].
BACKGROUND
The benefits of re-resection for recurrent intrahepatic cholangiocarcinoma (IHC) are unknown.


METHODS
We evaluated the comparative efficacy of different treatment schema for recurrent IHC following curative resection.


RESULTS
Among 46 patients, 26 underwent R0 resection, while 20 underwent R1 resection. There were 13 cases of recurrence in R1 patients (65%), and 19 in R0 patients (61%). Recurrent IHC cases were divided into 3 groups based on the treatment received after recurrence: re-resection (n=5), chemotherapy (n=13), and best supportive care (BSC) (n=8). Survival times were evaluated for each group; median survival times (MSTs) after recurrence were 26, 14, and 4 months for the re-resection, chemotherapy, and BSC groups, respectively (p=0.030). Next, we examined the patients who only had intrahepatic recurrence; MSTs after recurrence for re-resection, chemotherapy, and BSC groups were 26, 14, and 5 months, respectively (p=0.0018).


CONCLUSIONS
In recurrent IHC, survival time improves with re-resection or chemotherapy, when compared to BSC. In patients with intrahepatic recurrence only, re-resection is especially effective in prolonging survival.
Dept. of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine.
Sae
S
Murakami
Tetsuo
T
Ajiki
Taro
T
Okazaki
Taku
T
Matsumoto
Yuko
Y
Yoshida
Kenta
K
Shinozaki
Tadahiro
T
Goto
Sadaki
S
Asari
Makoto
M
Shinzeki
Masahiro
M
Kido
Ippei
I
Matsumoto
Takumi
T
Fukumoto
Yonson
Y
Ku
D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery*; D018281:Cholangiocarcinoma / Q000473:pathology / Q000601:surgery*; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D016896:Treatment Outcome